Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Hold at Zacks Research

Key Points

• Theravance Biopharma's stock rating was downgraded from "strong-buy" to "hold" by Zacks Research in a recent analysis.
• The stock has shown volatility, opening at $13.87, with a 52-week low of $7.88 and high of $14.55, and currently has a market capitalization of approximately $698.49 million.
• Institutional investors control 99.10% of Theravance Biopharma's shares, indicating strong confidence in the company's long-term prospects despite the recent rating changes.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts have also recently weighed in on TBPH. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research report on Tuesday, June 17th. B. Riley assumed coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a "buy" rating and a $28.00 price target on the stock. BTIG Research increased their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Finally, Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $23.00.

Theravance Biopharma Stock Down 4.1%

Shares of TBPH stock traded down $0.59 during trading hours on Monday, reaching $13.88. 465,356 shares of the company's stock were exchanged, compared to its average volume of 297,042. Theravance Biopharma has a fifty-two week low of $7.88 and a fifty-two week high of $14.55. The stock has a market capitalization of $699.00 million, a P/E ratio of 57.83 and a beta of 0.05. The business has a fifty day moving average price of $12.67 and a 200-day moving average price of $10.76.

Insider Activity

In other news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Theravance Biopharma by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock worth $18,579,000 after acquiring an additional 69,919 shares during the last quarter. Park West Asset Management LLC grew its position in shares of Theravance Biopharma by 0.6% in the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock valued at $16,112,000 after buying an additional 11,256 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Theravance Biopharma by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company's stock valued at $9,863,000 after buying an additional 3,416 shares during the last quarter. Bank of America Corp DE grew its position in shares of Theravance Biopharma by 16.5% in the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company's stock valued at $5,952,000 after buying an additional 76,417 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of Theravance Biopharma by 10.9% in the 4th quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company's stock valued at $4,665,000 after buying an additional 48,635 shares during the last quarter. Institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.